INTRODUCTION Clinical research in Alzheimer's disease (AD) lacks cohort diversity despite
being a global health crisis. The Asian Cohort for Alzheimer's Disease (ACAD) was formed …

Abstract Background Asian Americans and Canadians (ASACs) are the fastest growing
minority group in the US and Canada. ASACs are under‐sampled in Alzheimer's disease …

Abstract Background Asian Americans and Asian Canadians (ASACs) are the fastest
growing minority group in the US and Canada. Roughly 21% of ASACs will be 65 years or …

Background Alzheimer's disease (AD) is a leading cause of death worldwide. Despite the
global impact, clinical research in AD and, in particular, clinical trials, biomarker and …

Objectives: As the United States (US) population rapidly ages, the incidence of Alzheimer's
Disease and Related Dementias (ADRDs) is rising, with racial/ethnic minorities affected at …

Alzheimer's disease (AD) is a significant global health concern, with its impact amplified by
the aging population. Researchers have been working to unravel the intricate mechanisms …

Personalized medicine aims to tailor diagnosis and treatment based on an individual's
personal genetic make-up and other predictive biomarkers—rather than a one-size fits all …

Background Therapeutic trials in the preclinical stages of Alzheimer's disease (AD) typically
require large numbers of subjects in order to assess clinical benefit. The Duke AD …

Abstract Background The ADSP‐FUS is a National Institute on Aging (NIA) initiative focused
on identifying genetic risk and protective variants for Alzheimer Disease (AD) by expanding …

Background According to the Alzheimer's Association, Alzheimer's Disease (AD) occurs
much more frequently in African Americans than Caucasians. In spite of governmental …